Patients receiving cytochrome P enzyme-inducing anticonvulsant drugs (EIADs) (i.e. phenytoin, carbamazepine, Phenobarbital, primidone or oxcarbazepine) within  weeks of the start of the study treatment
Patients on enzyme-inducing anti-epileptic drugs (EIAED) are not eligible for treatment on this protocol; patients may be on non-enzyme inducing anti-epileptic drugs or not be taking any anti-epileptic drugs; patients previously treated with EIAED may be enrolled if they have been off the EIAED for  days or more prior to the first dose of PT
Patients who are currently receiving enzyme-inducing anti-convulsants are not eligible
Participants receiving an enzyme-inducing antiepileptic drug (EIAED) who cannot be transferred to a non-EIAED (e.g., levetiracetam, lacosamide, lamotrigine, etc.) prior to the initiation of protocol therapy
Patients receiving the following hepatic enzyme-inducing anti-seizure drugs (EIASD); for example:\r\n* Carbamazepine\r\n* Oxcarbazepine\r\n* Phenytoin\r\n* Fosphenytoin\r\n* Phenobarbital\r\n* Primidone
Patients who require enzyme inducing anti-convulsants to control seizures
Concomitant use of potent CYPA/ inducers, which include enzyme inducing antiepileptic drugs (EIAEDs) (see Appendix B), during the treatment phase of the study and within  weeks prior to starting treatment. Concurrent dexamethasone is allowed.
Enzyme-inducing anti-epileptic drugs (EIAEDs) within  days of randomization.
Patients requiring the use of enzyme-inducing anti-epileptic medication that includes but not limited to: phenytoin, carbamazepine, phenobarbital, primidone or oxcarbazepine are excluded
Concomitant use of potent CYPA/ inducers, which include enzyme inducing antiepileptic drugs (EIAEDs), during the treatment phase of the study and within  weeks prior to starting treatment
The use of seizure prophylaxis is allowed as long as patients are taking non-enzyme inducing anti-epileptic drugs (non-EIAED); if patients were previously on EIAEDs and these have been discontinued, they must have been discontinued for at least  weeks prior to treatment start; if patients require an anti-epileptic medication, then a CYPA non-EIAED can be used such as levetiracetam, valproic acid, gabapentin, topiramate or lacosamide
Participants are not permitted to receive enzyme inducing anti-epileptic drugs
AND asymptomatic and off systemic corticosteroids and/or enzyme-inducing anti-epileptic medications for brain metastases for > days prior to registration.
Patients must not be on enzyme-inducing anticonvulsants or other drugs that might interact with the cytochrome P enzyme system; if previously on an enzyme-inducing antiepileptic drugs (EIAED), patients must be off for at least  days prior to CED infusion
Patients requiring the use of enzyme-inducing anti-epileptic medication (phenytoin, carbamazepine, phenobarbital, primidone or oxcarbazepine) are not eligible for entry into the study
Received enzyme-inducing anti-epileptic agents within  days of study drug (e.g., carbamazepine, phenytoin, phenobarbital, primidone)
Receiving Enzyme Inducing Antiepileptic Drugs (EIAEDs) within  days of first dose.
Patients that are on enzyme-inducing anti-epileptic medications
Patients on an enzyme-inducing anti-convulsant who cannot be switched to a non-enzyme-inducing anti-convulsant with a  week wash-out period from time of drug discontinuation until day  of study treatment
Enzyme inducing anti-epileptic drugs
ENTRECTINIB INCLUSION CRITERIA: Patients with central nervous system (CNS) involvement, including leptomeningeal carcinomatosis, which is either asymptomatic or previously-treated and controlled, are allowed; the use of seizure prophylaxis is allowed as long as patients are taking non enzyme-inducing anti-epileptic drugs (non-EIAEDs); if patients were previously on EIAEDs and these have been discontinued, they must have been discontinued for at least  weeks prior to the start of entrectinib treatment; if patients require an anti-epileptic medication, a CYPA non-EIAED can be used such as levetiracetam, valproic acid, gabapentin, topiramate, or lacosamide; moderate inducers of CYP, such as dexamethasone or other glucocorticoids, may be used at the discretion of the investigator; patients requiring steroids must be at a stable or decreasing doses for at least  weeks prior to the start of entrectinib treatment
CAPMATINIB EXCLUSION CRITERIA: Known symptomatic brain metastases requiring increasing doses of steroid to manage CNS symptoms within  weeks prior to study entry\r\n* Patients with asymptomatic brain metastases may be enrolled at the discretion of the sponsor as long as the patient is stable and has not required increasing dose of steroids to manage CNS symptoms for at least  weeks prior to study enrollment\r\n* Patients requiring seizure prophylaxis must be taking non-enzyme-inducing anti-epileptic drugs (non-EIAED); if patients were previously on EIAEDs and these have been discontinued, they must be discontinued for at least  weeks prior to capmatinib administration; if patients require an antiepileptic medication, then a CYPA non-EIAED can be used such as levetiracetam, valproic acid, gabapentin, topiramate or lacosamide
Patients receiving treatment with any enzyme-inducing anticonvulsant
Patients may not be on an enzyme-inducing anti-epileptic drug (EIAED); if previously on an EIAED, patient must be off for at least  days prior to CED infusion
Patients requiring the use of enzyme-inducing anti-epileptic medication that includes: phenytoin, carbamazepine, phenobarbital, primidone or oxcarbazepine are excluded
Seizure disorder necessitating the use of enzyme-inducing antiepileptic drugs (EIAEDs); efforts may be made by the treating physician to change the antiepileptic drug from another agent to valproic acid or non-EIAED prior to excluding the patient from study
Patients who may be receiving any enzyme-inducing antiepileptic drugs (EIAED) within  weeks prior to registration, or any other prohibited medications within the washout period prior to registration
Patients is on an enzyme inducing anti-convulsants; if patients were previously on enzyme inducing antiepileptic drugs (EIAEDs) and these have been discontinued, patients must have been off the agent for at least  weeks prior to first study drug administration; for patients who need to start an antiepileptic drug (AED) or the AED needs to be changed, it is strongly recommended that all efforts should be made to use a non-EIAED
Participants taking an enzyme-inducing anti-epileptic drug (EIAED): phenobarbital, phenytoin, fosphenytoin, primidone, carbamazepine, oxcarbazepine, eslicarbazepine, rufinamide, and felbamate; participant must be off any EIAEDs for at least  days prior to planned start of study treatment; among non-EIAED, caution is recommended with use of valproic acid due to potential for drug interaction
Are taking concurrent enzyme-inducing antiepileptic drugs (EIAED).
Patients receiving treatment with any enzyme-inducing anticonvulsant
Treatment with concurrent enzyme-inducing anti-epileptic drugs (EIAEDs); patients previously treated with EIAEDs may be enrolled if they have been off the EIAED for  days or more prior to the first dose of mibefradil (mibefradil dihydrochloride)
Patients must not be taking Enzyme Inducing Anti-Epileptic Drug (EIAED). If previously on an EIAED, the patient must be off of it for at least two weeks prior to study treatment.
Subjects who have experienced a seizure or seizures within  months of study treatment or who are currently being treated with cytochrome P enzyme inducing anti-epileptic drugs for seizures (use of anti-epileptic drugs to control pain is allowed in subjects not suffering from seizures unless drug is excluded due to Cytochrome P A induction - phenytoin, carbamazepine, Phenobarbital.
Patients on enzyme-inducing anti-epileptic drugs (EIAED) are not eligible for treatment on this protocol; patients may be on non-enzyme inducing anti-epileptic drugs or not be taking any anti-epileptic drugs; patients previously treated with EIAED may be enrolled if they have been off the EIAED for  days or more prior to the first dose of AMG 
Participants taking an enzyme-inducing anti-epileptic drug (EIAED): phenobarbital, phenytoin, fosphenytoin, primidone, carbamazepine, oxcarbazepine, eslicarbazepine, rufinamide, and felbamate; participants must be off any EIAEDs for at least  days prior to starting study drug
Treatment with Enzyme-Inducing Anti-Epileptic Drugs within  weeks prior to Day 
Concurrent use of enzyme inducing anticonvulsants (e.g. phenytoin, phenobarbital, and carbamazepine) should be avoided
Patients on enzyme-inducing anti-epileptic drugs (EIAED) are not eligible for treatment on this protocol; patients may be on non-enzyme inducing anti-epileptic drugs or not be taking any anti-epileptic drugs; patients previously treated with EIAED may be enrolled if they have been off the EIAED for  days or more prior to the first dose of TRC
Treatment with non-enzyme inducing anti-seizure medications is allowed
Concurrent use of enzyme-inducing anti-epileptic drugs (EIAED); patients may be on non-enzyme inducing anti-epileptic drugs or not be taking any anti-epileptic drugs; patients previously treated with EIAED may be enrolled if they have been off the EIAED for  days or more prior to the first dose of MLN
For Cohort A: Has experienced a seizure or seizures within  months of study start or is currently being treated with cytochrome P enzyme (CYP) inducing anti-epileptic drugs for seizures
No enzyme-inducing anti-epileptic drugs (EIAED) such as carbamazepine, phenytoin, phenobarbital, or primidone within  days before Day .
Patients that are on enzyme-inducing anti-epileptic medications
Current or anticipated use of enzyme-inducing anti-epileptic drugs (EIAED)
Due to the potential interaction between nilotinib and enzyme-inducing anti-epileptic drugs (EIAED - phenytoin, fosphenytonin, carbamazepine, oxcarbazepine, phenobarbital, primidone, felbamate), only patients on non-enzyme inducing anti-epileptic drugs (NEIAED) or on no anti-epileptic drugs are eligible
The subject has received enzyme-inducing anti-epileptic agents within  days of study drug (eg, carbamazepine, phenytoin, phenobarbital, primidone)
Patients may not be receiving the following medications at the time of first dose of investigational drug:\r\n* Pharmacotherapy for known hepatitis B or C, tuberculosis, or human immunodeficiency virus (HIV) \r\n* Any of the following enzyme inducing anti-epileptic medications (EIAEDs): phenytoin, carbamazepine, oxcarbazepine, phenobarbital\r\n* Other chemotherapy, hormonal therapy, immunotherapy, other investigational agents, or biologic agents for the treatment of cancer except for bisphosphonates or denosumab
Patient is taking an enzyme inducing anti-epileptic drug (EIAED), including phenobarbital, phenytoin, fosphenytoin, primidone, carbamazepine, oxcarbazepine, eslicarbazepine, rufinamide, and felbamate; participates must be off of any EIAED for a least two weeks prior to starting the study drug
Patients that are on anticonvulsant medications should be switched, when possible, to a non-enzyme-inducing antiepileptic drug (non-EIAED); however, if that is not possible, they will not be excluded from the study
Patients must not be taking hepatic enzyme inducing anti-epileptic drug (EIAED) defined as:\r\n* EIAEDs (not allowed):\r\n** Carbamazepine (Tegretol, Tegretol XR, Carbatrol)\r\n** Oxcarbazepine (Trileptal)\r\n** Phenytoin (Dilantin, Phenytek)\r\n** Fosphenytoin (Cerebyx)\r\n** Phenobarbital\r\n** Primidone (Mysoline)\r\n* If previously on an EIAED, the patient must be off of it for at least two weeks prior to study treatment
Patients on enzyme-inducing anticonvulsive agents are excluded
Ongoing use of enzyme-inducing anti-epileptic agents (EIAEDs), unless  week washout has elapsed form last dose of EIAED
Patients receiving cytochrome P enzyme-inducing anticonvulsant drugs (EIADs) (i.e. phenytoin, carbamazepine, Phenobarbital, primidone or oxcarbazepine) are ineligible
Patients with uncontrolled brain metastases; patients who are on a stable dose of corticosteroids for more than  month or off corticosteroids for  weeks prior to study enrollment can be enrolled; enzyme-inducing anti-epileptic drugs are not permitted
Current or anticipated use of enzyme-inducing anti-epileptic drugs (EIAED)
Subjects receiving the following hepatic enzyme?inducing antiseizure drugs (EIASD):\r\n* Carbamazepine\r\n* Oxcarbazepine\r\n* Phenytoin\r\n* Fosphenytoin\r\n* Phenobarbital\r\n* Primidone
Concurrent use of enzyme-inducing antiepileptic drugs (EIAEDs), including phenytoin, carbamazepine, oxcarbazepine, fosphenytoin, phenobarbital, pentobarbital, or primidone
For mefloquine arm, patients must not be on enzyme inducing anticonvulsants (EIAED); if the treating physician elects to change the medication to a non-enzyme inducing agent, a -week wash out period will be required after stopping EIAED prior to initiation of treatment
(. continued) However, the use of non-enzyme inducing anti-epileptic medications is not mandatory. If enzyme-inducing antiepileptic drugs are used, monitoring of drug levels should be considered, as considered clinically appropriate by the treating physician.
Treatment with Enzyme-Inducing Anti-Epileptic Drugs within  weeks prior to Day 
Patients who are receiving concurrent enzyme-inducing anti-epileptic drugs (EIAEDs) (e.g., carbamazepine, oxcarbazepine, phenytoin, fosphenytoin, phenobarbital and primidone) or who received EIAEDs within  weeks prior to the first dose of study drug
Patients with brain metastases must not be taking primidone, carbamazepine, phenobarbital or phenytoin anticonvulsants (Enzyme-Inducing Anti-Epileptic Drugs). Patients changing from these anticonvulsants to others that are allowed must be off the drugs listed above for at least  week.
Patient taking enzyme-inducing anti-epileptic drug (EIAED) <  days of the first dose of PQR.
Current or expected use of a prohibited medication, including enzyme-inducing antiepileptic drugs (EIAEDs) during treatment with GSK.
Patient is currently receiving an enzyme-inducing anti-epileptic drug (EIAED). The patient must have discontinued EIAED therapy for at least two weeks prior to starting study drug.
Patients on enzyme-inducing anti-epileptic drugs (EIAED) are not eligible for treatment on this protocol; patients may be on non-enzyme inducing anti-epileptic drugs or not be taking any anti-epileptic drugs; patients previously treated with EIAED may be enrolled if they have been off the EIAED for  days or more prior to the first dose of AZD (MK-)
Use of cytochrome P enzyme-inducing anti-epileptic drugs (such as phenytoin, carbamazepine, or phenobarbital) is not allowed
Patient is currently receiving an enzyme inducing anti-epileptic drug. The patient must have discontinued EIAED therapy for at least two weeks prior to starting study drug. Non-enzyme inducing anti-epileptic medication is allowed, except those listed in the protocol
Patients must be at least  days off any enzyme inducing anti-epileptic drugs (EIAEDs) of the cytochrome P (CYP-) such as phenytoin, carbamazepine, phenobarbital
Enzyme inducing anti-epileptic drugs (EIAEDs) of the CYP- such as phenytoin, carbamazepine, phenobarbital
Patients can only be on non-enzyme inducing anti-convulsants; if they are on an enzyme inducing anti-convulsant, they may be converted to a non-enzyme inducing anticonvulsants
Patients must not be on enzyme-inducing antiepileptic drugs (EIAEDs)
Concurrent administration of cytochrome P, family , subfamily A, polypeptide  (CYPA) enzyme-inducing anti-epileptic drugs (EIAEDs) including phenytoin, phenobarbital, carbamazepine, oxcarbazepine or primidone
Patients on enzyme-inducing anti-epileptic drugs (EIAED) are not eligible for treatment on this protocol; patients may be on non-enzyme inducing anti-epileptic drugs or not be taking any anti-epileptic drugs; patients previously treated with EIAED may be enrolled if they have been off the EIAED for  days or more prior to the first dose of MLN (TAK-)
Use of enzyme-inducing anti-epileptic drugs (EIAED) within  days prior to the first dose of study drug.
Use of enzyme-inducing antiepileptic drugs (EIAEDs) within  days prior to the first dose of study drug